Bloomberg the Company & Products

Bloomberg Anywhere Login

Bloomberg

Connecting decision makers to a dynamic network of information, people and ideas, Bloomberg quickly and accurately delivers business and financial information, news and insight around the world.

Company

Financial Products

Enterprise Products

Media

Customer Support

  • Americas

    +1 212 318 2000

  • Europe, Middle East, & Africa

    +44 20 7330 7500

  • Asia Pacific

    +65 6212 1000

Communications

Industry Products

Media Services

Follow Us


Last $109.68 USD
Change Today -0.47 / -0.43%
Volume 1.1M
As of 8:10 PM 06/1/15 All times are local (Market data is delayed by at least 15 minutes).

Executive Profile*

James M. Daly MBA

Chief Commercial Officer and Executive Vice President, Incyte Corporation
AgeTotal Calculated CompensationThis person is connected to 15 board members in 1 different organizations across 3 different industries.

See Board Relationships
52$2,183,302
As of Fiscal Year 2014

Background*

Mr. James M. Daly, also known as Jim, MBA has been Chief Commercial Officer and Executive Vice President at Incyte Corporation since October 22, 2012. Mr. Daly is responsible for Incyte's commercial organization, including sales, marketing and business development. He served as Senior Vice President of North America Commercial Operations of Amgen Inc. since May 17, 2005 and also served as its Global Marketing and Commercial Development. He joined Amgen in early 2002 ...

Read Full Background

Corporate Headquarters*

1801 Augustine Cut-Off
Wilmington, Delaware 19803

United States

Phone: 302-498-6700
Fax: --

Board Members Memberships*

2014-Present
Director and Member of Compensation Committee

Education*

BS 1984
State University of New York
MBA 1985
State University of New York

Other Affiliations*

Annual Compensation*

Salary$520,968
Total Annual Compensation$520,968

Stock Options*

Restricted Stock Awards$320,039
All Other Compensation$6,298
Exercised Options277,776
Exercised Options Value$12,303,898
Unexercisable Options157,548
Unexercisable Options Value$7,140,694
Total Value of Options$19,444,592
Total Number of Options435,324

Total Compensation*

Total Annual Cash Compensation$902,975
Total Short Term Compensation$520,968
Other Long Term Compensation$326,337
Total Calculated Compensation$2,183,302
*Data is at least as current as the most recent Definitive Proxy.
 

Stock Quotes

Market data is delayed at least 15 minutes.

Company Lookup
Recently Viewed
INCY:US $109.68 USD -0.47

COMPETITOR COMPENSATION

NamePosition/
Company
Compensation
Richard F. Pops Chairman of the Board and Chief Executive Officer
Alkermes plc
$854.7K
Harvey J. Berger M.D.Principal Founder, Chairman, Chief Executive Officer, President and Chairman of Executive Committee
Ariad Pharmaceuticals Inc.
$1.4M
Jean-Jacques Bienaime MBAChief Executive Officer and Director
BioMarin Pharmaceutical Inc.
$916.0K
Jeffrey M. Leiden M.D., Ph.D.Chairman, Chief Executive Officer and President
Vertex Pharmaceuticals Incorporated
$1.1M
Bruce C. Cozadd Co-Founder, Executive Chairman and Chief Executive Officer
Jazz Pharmaceuticals Public Limited Company
$830.0K
Compensation as of Fiscal Year 2014.

Sponsored Financial Commentaries

Sponsored Links

Report Data Issue

To contact INCYTE CORP, please visit . Company data is provided by Capital IQ. Please use this form to report any data issues.

Please enter your information in the following field(s):
Update Needed*

All data changes require verification from public sources. Please include the correct value or values and a source where we can verify.

Your requested update has been submitted

Our data partners will research the update request and update the information on this page if necessary. Research and follow-up could take several weeks. If you have questions, you can contact them at bwwebmaster@businessweek.com.